Clinical Application of Melatonin in the Treatment of Cardiovascular Diseases: Current Evidence and New Insights into the Cardioprotective and Cardiotherapeutic Properties

Overview

Journal Cardiovasc Drugs Ther

Specialties Cardiology & Vascular Diseases
Pharmacology

Date 2020 Sep 14

PMID 32926271

Citations 15

Authors

Mohammad Hossein Pourhanifeh

Ehsan Dehdashtian

Azam Hosseinzadeh

Seyed Hashem Sezavar

Saeed Mehrzadi

Affiliations

Soon will be listed here.

Abstract

Cardiovascular diseases (CVDs) are the leading global cause of mortality and disability, tending to happen in younger individuals in developed countries. Despite improvements in medical treatments, the therapy and long-term prognosis of CVDs such as myocardial ischemia-reperfusion, atherosclerosis, heart failure, cardiac hypertrophy and remodeling, cardiomyopathy, coronary artery disease, myocardial infarction, and other CVDs threatening human life are not satisfactory enough. Therefore, many researchers are attempting to identify novel potential therapeutic methods for the treatment of CVDs. Melatonin is an anti-inflammatory and antioxidant agent with a wide range of therapeutic properties. Recently, several investigations have been carried out to evaluate its effectiveness and efficiency in CVDs therapy, focusing on mechanistic pathways. Herein, this review aims to summarize current findings of melatonin treatment for CVDs.

Citing Articles

Evaluating the Protective Effect of Melatonin on Atorvastatin-induced Mitochondrial Toxicity in Pancreatic Beta Cells.

Mehrzadi S, Hosseini A, Hosseinzadeh A Curr Drug Saf. 2024; 19(4):455-464.

PMID: 39188214 DOI: 10.2174/0115748863267262231025052412.

Insight into the cardioprotective effects of melatonin: shining a spotlight on intercellular Sirt signaling communication.

Yaghoobi A, Rezaee M, Hedayati N, Keshavarzmotamed A, Khalilzad M, Russel R Mol Cell Biochem. 2024; 480(2):799-823.

PMID: 38980593 DOI: 10.1007/s11010-024-05002-3.

Therapeutic Effects of Melatonin in the Regulation of Ferroptosis: A Review of Current Evidence.

Pourhanifeh M, Hosseinzadeh A, Koosha F, Reiter R, Mehrzadi S Curr Drug Targets. 2024; 25(8):543-557.

PMID: 38706348 DOI: 10.2174/0113894501284110240426074746.

New Perspectives on the Role and Therapeutic Potential of Melatonin in Cardiovascular Diseases.

Gu P, Wu Y, Lu W Am J Cardiovasc Drugs. 2024; 24(2):171-195.

PMID: 38436867 DOI: 10.1007/s40256-024-00631-x.

Mitochondrial Melatonin: Beneficial Effects in Protecting against Heart Failure.

Reiter R, Sharma R, de Almeida Chuffa L, Simko F, Dominguez-Rodriguez A Life (Basel). 2024; 14(1).

PMID: 38255703 PMC: 10820220. DOI: 10.3390/life14010088.

References

Lochner A, Marais E, Huisamen B . Melatonin and cardioprotection against ischaemia/reperfusion injury: What's new? A review. J Pineal Res. 2018; 65(1):e12490. DOI: 10.1111/jpi.12490. View

Bozzao L, Bava G . [Cerebral scintigraphy using Tc99m in the diagnosis of extensive subtentorial lesions by means of oblique postero-anterior projection]. Nunt Radiol. 1969; 35(2):117-26. View

Allende-Vigo M . Pathophysiologic mechanisms linking adipose tissue and cardiometabolic risk. Endocr Pract. 2010; 16(4):692-8. DOI: 10.4158/EP09340.RA. View

Roth G, Forouzanfar M, Moran A, Barber R, Nguyen G, Feigin V . Demographic and epidemiologic drivers of global cardiovascular mortality. N Engl J Med. 2015; 372(14):1333-41. PMC: 4482354. DOI: 10.1056/NEJMoa1406656. View

Hemati K, Kadijani A, Sayehmiri F, Mehrzadi S, Zabihiyeganeh M, Hosseinzadeh A . Melatonin in the treatment of fibromyalgia symptoms: A systematic review. Complement Ther Clin Pract. 2019; 38:101072. DOI: 10.1016/j.ctcp.2019.101072. View

Mehrzadi S, Hemati K, Reiter R, Hosseinzadeh A . Mitochondrial dysfunction in age-related macular degeneration: melatonin as a potential treatment. Expert Opin Ther Targets. 2020; 24(4):359-378. DOI: 10.1080/14728222.2020.1737015. View

Tengattini S, Reiter R, Tan D, Terron M, Rodella L, Rezzani R . Cardiovascular diseases: protective effects of melatonin. J Pineal Res. 2007; 44(1):16-25. DOI: 10.1111/j.1600-079X.2007.00518.x. View

Zaouali M, Reiter R, Padrissa-Altes S, Boncompagni E, Garcia J, Ben Abnennebi H . Melatonin protects steatotic and nonsteatotic liver grafts against cold ischemia and reperfusion injury. J Pineal Res. 2010; 50(2):213-21. DOI: 10.1111/j.1600-079X.2010.00831.x. View

10.

Li Z, Nickkholgh A, Yi X, Bruns H, Gross M, Hoffmann K . Melatonin protects kidney grafts from ischemia/reperfusion injury through inhibition of NF-kB and apoptosis after experimental kidney transplantation. J Pineal Res. 2009; 46(4):365-72. DOI: 10.1111/j.1600-079X.2009.00672.x. View

11.

Ates B, Yilmaz I, Geckil H, Iraz M, Birincioglu M, Fiskin K . Protective role of melatonin given either before ischemia or prior to reperfusion on intestinal ischemia-reperfusion damage. J Pineal Res. 2004; 37(3):149-52. DOI: 10.1111/j.1600-079X.2004.00148.x. View

12.

Koksal M, Oguz E, Baba F, Eren M, Ciftci H, Demir M . Effects of melatonin on testis histology, oxidative stress and spermatogenesis after experimental testis ischemia-reperfusion in rats. Eur Rev Med Pharmacol Sci. 2012; 16(5):582-8. View

13.

Tai S, Chen H, Lee E, Chen T, Lin H, Hung Y . Melatonin inhibits postischemic matrix metalloproteinase-9 (MMP-9) activation via dual modulation of plasminogen/plasmin system and endogenous MMP inhibitor in mice subjected to transient focal cerebral ischemia. J Pineal Res. 2010; 49(4):332-41. DOI: 10.1111/j.1600-079X.2010.00797.x. View

14.

Yip H, Chang Y, Wallace C, Chang L, Tsai T, Chen Y . Melatonin treatment improves adipose-derived mesenchymal stem cell therapy for acute lung ischemia-reperfusion injury. J Pineal Res. 2012; 54(2):207-21. DOI: 10.1111/jpi.12020. View

15.

Juybari K, Hosseinzadeh A, Ghaznavi H, Kamali M, Sedaghat A, Mehrzadi S . Melatonin As a Modulator of Degenerative and Regenerative Signaling Pathways in Injured Retinal Ganglion Cells. Curr Pharm Des. 2019; 25(28):3057-3073. DOI: 10.2174/1381612825666190829151314. View

16.

Dehdashtian E, Mehrzadi S, Yousefi B, Hosseinzadeh A, Reiter R, Safa M . Diabetic retinopathy pathogenesis and the ameliorating effects of melatonin; involvement of autophagy, inflammation and oxidative stress. Life Sci. 2017; 193:20-33. DOI: 10.1016/j.lfs.2017.12.001. View

17.

Dominguez-Rodriguez A, Abreu-Gonzalez P, Reiter R . Clinical aspects of melatonin in the acute coronary syndrome. Curr Vasc Pharmacol. 2009; 7(3):367-73. DOI: 10.2174/157016109788340749. View

18.

Dominguez-Rodriguez A, Abreu-Gonzalez P, Sanchez-Sanchez J, Kaski J, Reiter R . Melatonin and circadian biology in human cardiovascular disease. J Pineal Res. 2010; 49(1):14-22. DOI: 10.1111/j.1600-079X.2010.00773.x. View

19.

Mukherjee D, Ghosh A, Bandyopadhyay A, Basu A, Datta S, Pattari S . Melatonin protects against isoproterenol-induced alterations in cardiac mitochondrial energy-metabolizing enzymes, apoptotic proteins, and assists in complete recovery from myocardial injury in rats. J Pineal Res. 2012; 53(2):166-79. DOI: 10.1111/j.1600-079x.2012.00984.x. View

20.

Liu X, Chen Z, Chua C, Ma Y, Youngberg G, Hamdy R . Melatonin as an effective protector against doxorubicin-induced cardiotoxicity. Am J Physiol Heart Circ Physiol. 2002; 283(1):H254-63. DOI: 10.1152/ajpheart.01023.2001. View

21.

Dominguez-Rodriguez A, Abreu-Gonzalez P, Reiter R . The potential usefulness of serum melatonin level to predict heart failure in patients with hypertensive cardiomyopathy. Int J Cardiol. 2014; 174(2):415-7. DOI: 10.1016/j.ijcard.2014.04.044. View